443 related articles for article (PubMed ID: 29690860)
1. Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection.
Ji F; Zhang ZH; Zhang Y; Shen SL; Cao QH; Zhang LJ; Li SQ; Peng BG; Liang LJ; Hua YP
BMC Cancer; 2018 Apr; 18(1):460. PubMed ID: 29690860
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma.
Ji F; Fu SJ; Shen SL; Zhang LJ; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP
BMC Cancer; 2015 Mar; 15():116. PubMed ID: 25880619
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of LASS2 and TGF-β1 predicts poor prognosis in hepatocellular carcinoma.
Ruan H; Wang T; Yang C; Jin G; Gu D; Deng X; Wang C; Qin W; Jin H
Sci Rep; 2016 Sep; 6():32421. PubMed ID: 27581744
[TBL] [Abstract][Full Text] [Related]
4. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
5. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
[TBL] [Abstract][Full Text] [Related]
7. Combined Chibby and β-Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma.
Tsai MC; Huang CC; Wei YC; Liu TT; Lin MT; Yi LN; Lin PR; Wang CC; Chu TH; Hsiao CC; Hu TH; Tai MH
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192213
[TBL] [Abstract][Full Text] [Related]
8. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.
Liu R; Tang C; Shen A; Luo H; Wei X; Zheng D; Sun C; Li Z; Zhu D; Li T; Wu Z
Oncotarget; 2016 Dec; 7(51):85079-85096. PubMed ID: 27835881
[TBL] [Abstract][Full Text] [Related]
9. Aberrant Expression of CCAT1 Regulated by c-Myc Predicts the Prognosis of Hepatocellular Carcinoma.
Zhu HQ; Zhou X; Chang H; Li HG; Liu FF; Ma CQ; Lu J
Asian Pac J Cancer Prev; 2015; 16(13):5181-5. PubMed ID: 26225650
[TBL] [Abstract][Full Text] [Related]
10. Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter.
Sohn BH; Park IY; Lee JJ; Yang SJ; Jang YJ; Park KC; Kim DJ; Lee DC; Sohn HA; Kim TW; Yoo HS; Choi JY; Bae YS; Yeom YI
Gastroenterology; 2010 May; 138(5):1898-908. PubMed ID: 20038433
[TBL] [Abstract][Full Text] [Related]
11. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
[TBL] [Abstract][Full Text] [Related]
12. Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis.
Lu Y; Wu LQ; Li CS; Wang SG; Han B
Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):174-8. PubMed ID: 18397854
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of activated Cdc42-associated kinase1 (Ack1) predicts tumor recurrence and poor survival in human hepatocellular carcinoma.
Wang B; Xu T; Liu J; Zang S; Gao L; Huang A
Pathol Res Pract; 2014 Dec; 210(12):787-92. PubMed ID: 25445114
[TBL] [Abstract][Full Text] [Related]
14. LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling.
Liu J; Xu R; Mai SJ; Ma YS; Zhang MY; Cao PS; Weng NQ; Wang RQ; Cao D; Wei W; Guo RP; Zhang YJ; Xu L; Chen MS; Zhang HZ; Huang L; Fu D; Wang HY
Theranostics; 2020; 10(17):7527-7544. PubMed ID: 32685003
[TBL] [Abstract][Full Text] [Related]
15. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma.
Zhu PP; Yuan SG; Liao Y; Qin LL; Liao WJ
World J Gastroenterol; 2015 Jun; 21(23):7254-63. PubMed ID: 26109813
[TBL] [Abstract][Full Text] [Related]
16. High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy.
Wang H; Jiang S; Zhang Y; Pan K; Xia J; Chen M
World J Surg Oncol; 2014 Jul; 12():226. PubMed ID: 25037578
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of miR-21 predicts poor prognosis in patients with hepatocellular carcinoma.
Huang CS; Yu W; Cui H; Wang YJ; Zhang L; Han F; Huang T
Int J Clin Exp Pathol; 2015; 8(6):7234-8. PubMed ID: 26261620
[TBL] [Abstract][Full Text] [Related]
18. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients.
Chen YL; Lin PY; Ming YZ; Huang WC; Chen RF; Chen PM; Chu PY
BMC Cancer; 2017 Jul; 17(1):474. PubMed ID: 28687090
[TBL] [Abstract][Full Text] [Related]
19. Low levels of glycoprotein 96 indicate a worse prognosis in early-stage hepatocellular carcinoma patients after hepatectomy.
Ji F; Zhang Y; Zhu ZB; Guo Y; Shen SL; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP
Hum Pathol; 2019 Apr; 86():193-202. PubMed ID: 30529751
[TBL] [Abstract][Full Text] [Related]
20. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
